The present invention relates to a method of isolating a mesenchymal stem cell population from the amniotic membrane of the umbilical cord, the method comprising cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco’s modified eagle medium), F12 (Ham’s F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population isolated from the amniotic membrane of the umbilical cord, wherein at least about 90 % or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.本發明涉及一種從臍帶羊膜分離間質幹細胞群的方法，該方法包括在包含DMEM (Dulbecco’s modified eagle medium，達爾伯克改良伊格爾培養基)、F12 (Ham's F12培養基)、M171(培養基171)，以及FBS (Fetal Bovine Serum，胎牛血清)的培養基中培養臍帶組織。本發明亦涉及一種從臍帶的羊膜分離的間質幹細胞群，其中該幹細胞群的至少約90%或更多的細胞表現下列標記物中的每一種：CD73、CD90以及CD105，並缺乏表現以下標記物：CD34、CD45以及HLA-DR。本發明還涉及一種此間質幹細胞群的醫藥組合物。
